A database of consented, clinical-prescreened, genetically-characterised rare cancer patients to accelerate the delivery of precision medicine trials.

The RareCan platform uses liquid biopsies to generate genetic data not available in clinical practice, and screens patients against a panel of target tumour mutations being used across a portfolio of our clients’ development programmes. This is a subscription service, through which clients can access patients with the genetic mutations they are targeting while sharing the cost of patient identification and screening.

Precision Medicine Platform

Our partners

We collaborate with partners across the healthcare system to support patients with rare cancers.

NHS Newcastle
Cancer Research Horizons
Testicular Cancer UK
Neuroendocrine Cancer
Sarcoma UK
National Horizons Centre Logo